SITC 2020 focused on checkpoint inhibitors with anti-PD-1s taking a major share of the limelight, as discussed in various sessions it was all about raising the bar. 65% of all presentations were about anti-PD-1 in various phases of development. There was not a great foray into different types of tumors. The research community and pharma were focused on improving the outcomes of anti-PD-1s by using various strategies around combinations and addressing the use of biomarkers in earlier treatment approaches. As always it was a great forum to get a round-up of all other IOs. Please reach out to CI Scientists if you need anything on IO’s and more